



Government of **Western Australia**
Department of **Health**

Preview of Twelfth Edition Changes

Antimicrobial resistance (AMR)

WA Clinical Coding Authority

Purchasing and System Performance Division

May 2022, updated December 2022


Produced with resources available prior to release of IHPA Education

Version history


Version	Date Released	Author	Amendment
1.0	May 2022	WA Clinical Coding Authority	
2.0	December 2022	WA Clinical Coding Authority	Revisions: <ul style="list-style-type: none">• Amendments to U93 instructions and carrier status in diagrams (pages 3-4)• ESBL producing organism classification (page 5)• Documentation and abstraction of resistance (page 5)• Examples 2-3 (pages 7-8)

12th Edition code assignment for antimicrobial resistance


1. Assign a code for the infection if it meets ACS 0001 *Principal diagnosis* or 0002 *Additional diagnosis* criteria for code assignment.



2. Assign an additional code(s) from B95-B97 *Bacterial and viral agents as the cause of diseases classified to other chapters* to specify the microbial agent(s) if not already specified in the infection code.




3. Assign a code(s) from Z14-Z16 *Resistance to antimicrobial drugs* if resistance is documented in the current episode or microbial agent is ESBL producing (eg. E.coli, Kleb. pneumoniae).



4. Assign U93 *Extended spectrum beta-lactamase [ESBL] producing organism* if microbial agent is documented as an ESBL producing organism.

Major changes to antimicrobial (AMR) classification in 12th Edition



IHPA clarification during the ITG process regarding AMR classification in 12th Edition

- If an infection meets ACS 0001 or ACS 0002 criteria for coding, **drug resistance is always coded when documented in the current episode.**
- Resistance (Z14-Z16) cannot be coded directly from a microbiology report without supporting documentation in the current episode. To assign a code from Z14-Z16 'resistance' must be documented in the current episode, then specificity may be abstracted from the microbiology report in accordance with ACS 0010 *Clinical documentation and general abstraction guidelines*. For example, "R" noted on a microbiology report cannot be used in isolation to assign a Z14-Z16 code.
 - Exception: Resistance is inherent in ESBL producing organisms (ie. certain strains of Escherichia coli [E. coli] and Klebsiella pneumoniae). For organisms specified as ESBL producing, 'resistance' does not need to be specifically documented in the current episode to assign a Z14-Z15 code – the resistance information can be taken directly from the microbiology report.
 - Note: While it is not acceptable to assign a code from Z14-Z16 *Resistance to antimicrobial drugs* by only abstracting the "R" (for resistance) documented on pathology reports, if a clinician documents "R" or transcribes results containing "R" into the body of the current episode of care or onto the discharge summary, this can be considered to be synonymous with the term "resistance" and used to inform code assignment.
 - As per the logic in IHACPA's Twelfth Edition FAQ: *Antimicrobial drug resistance* (TN1601, effective 1 Oct 2022) which states, "where a clinician transcribes information (copied by hand or transferred electronically) from a pathology result into the progress notes, the entry is part of the clinician's documentation within the body of the episode of care", electronic discharge summaries form part of the medical record and the contents can be used as supporting documentation for assignment of a code from Z14-Z16.
- "ESBL producing" needs to be specifically documented with E. Coli and Klebsiella pneumoniae for assignment of a code from Z14-Z15 and U93 *Extended spectrum beta-lactamase [ESBL] producing organism*. A query has been sent to IHACPA to confirm this instruction as it was not clarified by the 12th Edition FAQ process.
- A code from Z14-Z15 must be assigned with U93 *Extended spectrum beta-lactamase [ESBL] producing organism*, as per the ICD-10-AM Tabular List *Instructional* note at U93: "Code first resistance to antimicrobial drug (Z14-15)" and ACS 0112: "Assign codes from block Z14-Z16 where... there is documentation of an infection due to an ESBL producing organism".
- New codes B37.82 *Candida albicans [C. albicans]* and B37.83 *Candida auris [C. auris]* are assigned if they provide specificity about the species of Candida. Code first the Candidiasis (ie. B37.0–B37.7, B37.81, B37.89, B37.9, P37.5-), even if the site is unknown (ie. B37.9).

Coding Examples

Example 1 – Infection with resistance to multiple antimicrobials

Patient admitted for treatment of pneumonia. Sputum culture identified *Streptococcus pneumoniae*, resistant to clindamycin, dicloxacillin and benzylpenicillin. Ward round documentation by treating clinician: “Strep. pneumoniae pneumonia resistant to multiple antibiotics”.

11th Edition code assignment	12th Edition code assignment
J13 <i>Pneumonia due to Streptococcus pneumoniae</i>	J13 <i>Pneumonia due to Streptococcus pneumoniae</i>
Z06.51 <i>Resistance to penicillin</i>	Z14.01 <i>Resistance to beta-lactamase sensitive [first generation] penicillins</i>
Z06.69 <i>Resistance to other specified antibiotics</i>	Z14.02 <i>Resistance to beta-lactamase resistant [second generation] penicillins</i>
	Z15.1 <i>Resistance to macrolides, lincosamides and streptogramins</i>
<ul style="list-style-type: none"> As per 11th Ed. ACS 0112, Z06.51 and Z06.69 are assigned, in addition to a code for the infection (J13), to identify resistance to dicloxacillin, benzylpenicillin and clindamycin. In 11th Edition it was unclear whether documentation of ‘resistance’ also needed to indicate the resistance was ‘significant’ before assigning a ‘Z’ code, therefore, Z06.51 and Z06.69 were inconsistently assigned by coders. 	<ul style="list-style-type: none"> The treating clinician has documented ‘resistance’ in the current episode, therefore, as per 12th Ed. ACS 0112, codes for resistance (Z14-Z16) are to be assigned. As per IHPA’s clarification during the ITG process regarding ACS 0112 and ACS 0010, information on the microbiology report can be abstracted from to add specificity regarding the type of resistance. Note: As per 12th Ed. ACS 0112, Z15.7 <i>Resistance to multiple antibiotics</i> and Z16.7 <i>Resistance to multiple antimicrobial drugs</i> should only be assigned where the resistance is due to multiple unspecified antimicrobials.

Example 2 – Infection with ESBL producing organism, antimicrobial resistance specified

Patient admitted for treatment of cellulitis of shin. Wound swab identified *Klebsiella pneumoniae* - ESBL producing resistant to ampicillin. Principal diagnosis on discharge summary: “Shin cellulitis due to *Klebsiella*”.

11th Edition code assignment	12th Edition code assignment
<p>L03.13 <i>Cellulitis of lower limb</i></p> <p>B96.1 <i>Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified to other chapters</i></p> <p>Z06.53 <i>Extended spectrum beta-lactamase (ESBL) resistance</i></p>	<p>L03.13 <i>Cellulitis of lower limb</i></p> <p>B96.1 <i>Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified to other chapters</i></p> <p>Z14.11 <i>Resistance to aminopenicillins</i></p> <p>U93 <i>Extended spectrum beta-lactamase [ESBL] producing organism</i></p>
<ul style="list-style-type: none"> Z06.53 is assigned for extended spectrum beta-lactamase (ESBL) resistance as per NCA Q3171 <i>Extended spectrum beta-lactamase (ESBL) resistance</i> (effective 1 Jan 2017 to 30 Jun 2022) . 	<ul style="list-style-type: none"> A code from Z14-Z15 must be assigned with U93, as per the ICD-10-AM Tabular List <i>Instructional note</i>: “Code first resistance to antimicrobial drug (Z14-Z15)” and 12th Ed. ACS 0112, <i>Infection due to an ESBL producing organism</i> which states: “assign one or more codes from block Z14-Z16 to identify resistance”. As per IHPA’s clarification during the ITG process regarding 12th Ed. ACS 0112, resistance does not need to be specifically documented in the current episode; and can be coded from the swab results alone because it’s inherent in ESBL producing organisms.

Example 3 – Carrier of ESBL producing organism, antimicrobial resistance not specified

Patient admitted for knee replacement due to OA. Micro-alert form states “Resistant ESBL E. Coli carrier”. Patient is given a single room and strict infection control precautions are implemented.

11th Edition code assignment	12th Edition code assignment
M17.1 <i>Other primary gonarthrosis</i>	M17.1 <i>Other primary gonarthrosis</i>
Z22.3 <i>Carrier of other specified bacterial diseases</i>	Z22.3 <i>Carrier of other specified bacterial diseases</i>
	Z15.9 <i>Resistance to antibiotic, unspecified</i>
	U93 <i>Extended spectrum beta-lactamase [ESBL] producing organism</i>
<ul style="list-style-type: none"> Z22.3 is assigned in accordance with ACS 0002. 	<ul style="list-style-type: none"> Z22.3 is assigned as per 12th Ed. ACS 0112 and ACS 0002. As per TN1601 <i>Twelfth Edition FAQ: Carrier of extended spectrum beta-lactamase (ESBL) producing organism</i>, Z15.9 and U93 are assigned because resistance has been specified. Where resistance is not documented with carrier of ESBL, assign only Z22.3 as the guidelines for ACS 0112 do not apply. A query to IHACPA has been sent to clarify the instructions in this FAQ. If specificity of antimicrobial resistance is not documented for an ESBL producing organism, assign Z15.9 <i>Resistance to antibiotic, unspecified</i> because all ESBL producing organisms are resistant. This follows the ICD-10-AM Tabular List <i>Instructional</i> note at U93 which states, “Code first resistance to antimicrobial drug (Z14-Z15)” and ACS 0112, <i>Infection due to an ESBL producing organism</i> which states to “assign one or more codes from block Z14-Z16 to identify resistance”. Z16.9 <i>Resistance to antimicrobial, unspecified</i> (ie. drug resistance NOS) is not assigned because ESBL are enzymes produced by certain <u>bacteria</u>. U93 is only assigned with codes from Z14-Z15 as per the <i>Instructional</i> note at U93.

Example 4 – Infection with Candida species identified

Patient admitted for management of dementia. Clinician reviewed the patient and documented ‘oral thrush, for Nilstat.’ A mouth swab was taken which identified *Candida albicans*.

11th Edition	12th Edition
F03 <i>Unspecified dementia</i>	F03 <i>Unspecified dementia</i>
B37.0 <i>Candidal stomatitis</i>	B37.0 <i>Candidal stomatitis</i>
	B37.82 <i>Candida albicans [C. albicans]</i>

11th Edition

- B37.0 is assigned for oral thrush due to any species of *Candida* following 11th Ed. ICD-10-AM Index pathway: **Thrush, -oral.**

12th Edition

- In 12th Ed., B37.82 and B37.83 are new codes assigned to add specificity about the species of *Candida* in addition to a code assigned for the site of *Candida*.
- As per the 12th Ed. ICD-10-AM Tabular List *Instructional* note at B37.0: Use additional code (B37.82, B37.83) to identify *Candida* species.

Possible errors in 12th Edition

Excerpt from 12th Ed. ACS 0112 *Infection with drug resistant micro-organisms*

INFECTION DUE TO AN ESBL PRODUCING ORGANISM

Where there is documentation of an infection due to an extended spectrum beta-lactamase (ESBL) producing organism, assign:

- a code for the infection in accordance with ACS 0001 *Principal diagnosis* or ACS 0002 *Additional diagnoses*
- a code from block B95–B96 (if not inherent in the infection code)
- one or more codes from block **Z14–Z16** to identify resistance to antimicrobial drugs
- U93 *Extended spectrum beta-lactamase [ESBL] producing organism*

The circled code range should be Z14-Z15, rather than Z14-Z16, as per the 12th Ed. ICD-10-AM Tabular List *Instructional* note at U93 which states, “Code first resistance to antimicrobial drug (Z14-Z15)”.

New infection codes in ICD-10-AM 12th Edition

Chapter 1 *Certain infectious and parasitic diseases (A00-B99)*

A49.81 *Bacteroides (fragilis) infection, unspecified site*
A49.82 *Burkholderia infection not elsewhere classified, unspecified site*
A49.83 *Campylobacter infection, unspecified site*
A49.84 *Escherichia coli [E. coli] infection, unspecified site*
A49.85 *Klebsiella pneumoniae [K. pneumoniae] infection, unspecified site*
A49.86 *Proteus (mirabilis), Morganella (morganii) and Providencia (rettgeri) infection, unspecified site*
A49.87 *Pseudomonas (aeruginosa) infection, unspecified site*
A49.89 *Other bacterial infection of unspecified site*

B37.82 *Candida albicans [C. albicans]*
B37.83 *Candida auris [C. auris]*
B37.89 *Candidiasis of other sites*

B95.71 *Staphylococcus argenteus as the cause of diseases classified to other chapters*
B95.79 *Other Staphylococcus as the cause of diseases classified to other chapters*

B96.41 *Proteus (mirabilis) as the cause of diseases classified to other chapters*
B96.42 *Morganella (morganii) as the cause of diseases classified to other chapters*
B96.43 *Providencia (rettgeri) as the cause of diseases classified to other chapters*

B96.83 *Acinetobacter baumannii [A. baumannii] as the cause of diseases classified to other chapters*
B96.84 *Burkholderia (mallei) (pseudomallei) as the cause of diseases classified to other chapters*
B96.85 *Campylobacter as the cause of diseases classified to other chapters*
B96.86 *Clostridioides [Clostridium] difficile [C. difficile] as the cause of diseases classified to other chapters*
B96.87 *Other enterobacterales as the cause of diseases classified to other chapters*
B96.89 *Other specified bacterial agents as the cause of diseases classified to other chapters*

Chapter 21 *Factors influencing health status and contact with health services (Z00-Z99)*

Z14 *Resistance to beta-lactam antibiotics*

Z14.0 *Resistance to narrow spectrum penicillins*

Z14.01 *Resistance to beta-lactamase sensitive [first generation] penicillins*
Z14.02 *Resistance to beta-lactamase resistant [second generation] penicillins*

Z14.1 *Resistance to extended spectrum penicillins*

Z14.11 *Resistance to aminopenicillins*
Z14.12 *Resistance to carboxypenicillins*
Z14.13 *Resistance to ureidopenicillins*

Z14.2 *Resistance to cephalosporins*

Z14.21 *Resistance to first generation cephalosporins*
Z14.22 *Resistance to second generation cephalosporins*
Z14.23 *Resistance to third generation cephalosporins*
Z14.24 *Resistance to fourth generation cephalosporins*
Z14.25 *Resistance to fifth generation cephalosporins*

Z14.3 *Resistance to carbapenems, penems and monobactams*

Z14.31 *Resistance to carbapenems*
Z14.32 *Resistance to penems*
Z14.33 *Resistance to monobactams*

Z14.4 *Resistance to penicillin-based antibiotic with beta-lactamase inhibitor*

Z14.8 *Resistance to other beta-lactam antibiotics*

Z14.9 *Resistance to beta-lactam antibiotic, unspecified*

Z15 Resistance to other antibiotics

Z15.0 Resistance to sulphonamides and trimethoprim

Z15.1 Resistance to macrolides, lincosamides and streptogramins

Z15.2 Resistance to aminoglycosides

Z15.3 Resistance to quinolones

Z15.30 Resistance to quinolones, unspecified

Z15.31 Resistance to fluoroquinolones

Z15.39 Resistance to other specified quinolones

Z15.4 Resistance to glycopeptides

Z15.41 Resistance to vancomycin

Z15.49 Resistance to other specified glycopeptides

Z15.7 Resistance to multiple antibiotics

Z15.8 Resistance to other specified antibiotic

Z15.81 Resistance to polymyxins

Z15.82 Resistance to tetracyclines

Z15.83 Resistance to imidazole derivatives

Z15.84 Resistance to oxazolidinones

Z15.89 Resistance to other specified antibiotics

Z15.9 Resistance to antibiotic, unspecified

Z16 Resistance to other antimicrobials

Z16.0 Resistance to antimycotics

Z16.1 Resistance to antimycobacterials

Z16.2 Resistance to antivirals

Z16.3 Resistance to antiparasitic drugs

Z16.30 Resistance to antiparasitic drugs, unspecified

Z16.31 Resistance to anthelmintic drugs

Z16.32 Resistance to antimalarial drugs

Z16.39 Resistance to other specified antiparasitic drugs

Z16.7 Resistance to multiple antimicrobials

Z16.8 Resistance to other specified antimicrobials

Z16.9 Resistance to antimicrobial, unspecified

Chapter 22 Codes for special purposes (U00-U49, U78-U88, U91-U93)

U93 Extended spectrum beta-lactamase [ESBL] producing organism

**This document can be made available in alternative formats
on request for a person with disability.**

© Department of Health 2022

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the *Copyright Act 1968*, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.